Stockwinners Market Radar for May 16, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:27 EDT Cathie Wood's ARK Investment bought 208K shares of Twilio today

18:35 EDT Crane CEO sells $2.87M in common stock - In a regulatory filing, Crane disclosed that its CEO Max Mitchell sold 37.5K shares of common stock on May 15th in a total transaction size of $2.87M.

18:17 EDT Clear Channel Outdoor 'taking meaningful action' to improve capital structure - Clear Channel Outdoor Holdings issued the following statement in response to a filing from Legion Partners Asset Management. "The Clear Channel Board of Directors and management team always welcome constructive conversations with our shareholders, including Legion. The Board and management are taking meaningful action to enhance the company's strategic position and improve its capital structure, including through our ongoing review of alternatives for our European businesses and evaluating a range of other strategic opportunities to enhance value. Our Board remains focused on delivering profitable growth, strengthening our balance sheet, and further demonstrating the operating leverage of our model. The management team and Board are confident in Clear Channel's strategic direction and will continue to act in the best interests of all shareholders to drive maximum value creation."

18:15 EDT Audacy to appeal determination by NYSE to commence delisting proceedings - Audacy announced that the New York Stock Exchange publicly announced and notified the company that the NYSE elected to commence proceedings to delist the company's Class A Common Stock from the NYSE pursuant to Section 802.01D of the NYSE Listed Company Manual, which states that the NYSE will consider commencing delisting procedures when a company's listed securities experience an abnormally low selling price. The NYSE will apply to the Securities and Exchange Commission to delist the company's common stock pending completion of applicable procedures. While the NYSE pursues such procedures, trading in the company's common stock on the NYSE is suspended but the common stock will continue to be able to be traded over the counter. The company intends to appeal this determination by the NYSE by filing a written request within ten business days after receiving the notice. If the company is successful in its appeal of the NYSE's decision to suspend trading in the common stock and initiate delisting proceedings pursuant to Section 802.01D, the common stock may resume trading on the NYSE. "Over the past few years, we have taken a number of transformational actions to give Audacy a leading, differentiated, and scaled position in the dynamic audio space, including podcasting, streaming audio, and our leadership presence across the country's largest markets and our unrivaled strength in sports and news radio. While we are disappointed by the NYSE's decision, we are hopeful we will find our way back to the exchange later this year as we execute our action plans which include a reverse stock split to satisfy NYSE rules, the continued execution of our liability management plans and working with our financial advisors to refinance our debt. Further, as macroeconomic conditions stabilize, we believe we will benefit from a general market recovery and will be able to capitalize on our investments in strategic transformation that position Audacy well for the future," said David Field, Chairman, President and CEO of Audacy.

18:02 EDT Legion reports 5.1% active stake in Clear Channel, urges broad strategic review - Legion reports a 5.1% active stake in Clear Channel Outdoor in a 13 D filing. Legion purchased the securities of Clear Channel Outdoor on that belief "that such securities, when purchased, were undervalued and represented an attractive investment opportunity... On May 16 Legion delivered a letter to the Clear Channel Outdoor Board expressing the belief that the current market price of the Shares does not reflect the intrinsic value. As detailed in the letter, in the Legion's view, Clear Channel strategic review of non-core assets in Europe is an appropriate and necessary strategic initiative but may not sufficiently improve the market price of the Shares or the Clear Channel capital structure. In addition, the Reporting Persons noted their concern with the scope and pace of the current strategic review process and belief that the Board needed to consider, with greater urgency, a broader strategic review process, including potential divestitures of other non-core assets and select U.S. assets, or a sale of Clear Channel ."

17:46 EDT Epsilon Energy announces second drilling focused transaction in Permian Basin - Epsilon Energy reported an investment in Ector County, Texas with material follow-on development opportunities. Epsilon announced a second drilling focused transaction in the Permian Basin. The acquired assets are a 25% working interest in 12,373 gross acres located in Ector County, Texas on the Central Basin Platform, operated by a Midland-based private operator. The position is on an emerging Mississippian play proximal to several other active public and private operators. The Company will participate in the drilling and completion of 2 gross wells, both 10,000' laterals, over the remainder of 2023. Epsilon signed definitive agreements to acquire a 25% working interest in a 1,297 acre unit and a 25% working interest in a 11,076 acre position, both in the same play alongside the same operator. Drilling activity is expected to commence on the 11,076 acreage position in 2024. Initial plans call for an additional 2-4 gross wells in 2024 with plans expected to be finalized later this year. At an initial assumption of 2 wells per section spacing, this adds 20 gross potential development locations to the Company's inventory. The total consideration net to Epsilon for the transaction, including 2023 capital expenditures, is approximately $14M. The Company expects these investments will contribute to the Company's production, revenue, and cash flow starting in the second half of 2023.

17:26 EDT Tesla CEO says intend to roll out Tesla insurance later this year - Says would like it to be nationwide insurance.

17:02 EDT Intercept granted FDA ODD for the fixed-dose combination of OCA, bezafibrate - Intercept Pharmaceuticals announced that the U.S. FDA has granted orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate, a peroxisome proliferator-activated receptor agonist, for the potential treatment of individuals with primary biliary cholangitis. Intercept has two ongoing Phase 2 studies that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. The company expects to complete planned interim analyses from both ongoing Phase 2 studies in 2023, with the first data being presented at the 2023 European Association for the Study of the Liver Congress, which will be held from June 21-24, 2023, in Vienna, Austria. The planned interim analyses from these Phase 2 studies, in addition to Phase 1 and preclinical data, will serve as the basis of a potential end-of-phase 2 meeting with the FDA.

16:57 EDT Zoom Video CFO Steckelberg sells $206K in company shares - The CFO of Zoom Video Kelly Steckelberg disclosed in a regulatory filing that he had sold 3,224 shares of company stock at $63.88 per share on May 12, for a total transaction amount of $$205,948.

16:45 EDT Booking Holdings CEO sells $1.98M, CFO sells $1.44M in common stock - In regulatory filings, Booking Holdings disclosed that its CEO Glenn Fogel sold 750 shares of common stock and CFO David Goulden sold 550 shares of common stock on May 15th in respective transaction sizes of $1.98M and $1.44M.

16:36 EDT Carriage Services announces national pact to grow pre-arranged services - Carriage Services announced a landmark national agreement with National Guardian Life Insurance Company, NGL , which has provided insurance solutions for over 100 years, and Precoa, the premier pre-arranged funeral sales and marketer in the death care industry. This strategic partnership will deliver exceptional pre-arranged funeral services and offerings across the Carriage Services platform, empowering families with unparalleled peace of mind and an elevated customer experience. "We are excited to announce this transformative national agreement and partnership between NGL, Precoa and Carriage Services," said Carlos Quezada, Vice Chairman, President and Chief Operating Officer of Carriage Services. "By combining the expertise and heritage of NGL, the innovative and industry-leading preneed solutions of Precoa and the customer-centric approach of Carriage Services, we are elevating our pre-arranged funeral offering across all Carriage locations and ensuring families receive personalized support and peace of mind as they plan for their end-of-life celebration. In addition, this transformative partnership will enable Carriage to reach new audiences, forge deeper customer relationships and to grow market share, ultimately creating value for our shareholders."

16:36 EDT Ansys to acquire Diakopto, terms not stated - Ansys "announced that it has entered into a definitive agreement to acquire Diakopto. A provider of differentiated EDA solutions to accelerate integrated circuit development, Diakopto focuses on helping resolve critical issues caused by layout parasitics. The transaction is subject to the satisfaction of customary closing conditions and is expected to close in the second quarter of 2023. It is not expected to have a material impact on Ansys' consolidated financial statements in 2023."

16:33 EDT RumbleON's two largest holders criticize board's severance payments decision - William Coulter and Mark Tkach, who together hold approximately 32.0% of the outstanding Class B shares of common stock of RumbleOn, sent a letter to the RumbleOn Board of Directors, criticizing the Board's recent decision to accelerate severance payments to former Director and COO Peter Levy, and to shield those payments from accountability.

16:31 EDT PulteGroup names Matthew Koart as Chief Operating Officer - PulteGroup announced that experienced industry veteran Matthew Koart has been named as Executive Vice President and Chief Operating Officer. Koart replaces John Chadwick who retired effective April 21, 2023. Koart will join the company on May 18, 2023. Since 2011, Koart has been President of Koart Residential, a company he founded,

16:29 EDT Keysight Technologies jumps 8% to $158.39 after Q2 earnings beat, Q3 guidance

16:26 EDT Western Alliance reports quarter-to-date deposit growth over $2B as of May 12 - Western Alliance disclosed a Q2 investor update, in which it stated in part: "WAL's deposit balances stabilized by March 20 and resumed growth trajectory. QTD deposit growth exceeded $2B as of May 12, up from $47.6B as of March 31. Insured Deposit Strenght - greater than 79% as of May 12, up from 68% as of March 31" Reference Link

16:20 EDT Scansource discloses ransomware attack on its systems - ScanSource "announced that it was subject to a ransomware attack that has impacted some of its systems. Upon discovering the incident on May 14, 2023, the Company immediately launched an investigation and implemented its Incident Response Plan. ScanSource is actively managing the incident and is taking steps toward remediation. The Company is working closely with forensic and cybersecurity experts to investigate the extent of the incident, minimize disruption and mitigate the situation. ScanSource has notified law enforcement authorities."

16:18 EDT BioVie presents data for potential trial of NE3107 to treat PD at IAPRD - BioVie announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison's Disease was presented at the 2023 World Congress on Parkison's Disease and Related Disorders, IAPRD, held in Chicago, IL May 13-16. In a poster presentation titled Rationale for a Potentially Pivotal Study of NE3107 in Parkinson's Disease , outcomes from two previously reported studies that assessed the potential of NE3107 in the treatment of Parkinson's Disease PD and Alzheimer's Disease AD were highlighted. The Company's NM201 study was an exploratory, Phase 2, double-blind, placebo-controlled study, that assessed the safety, tolerability, and efficacy of NE3107 or placebo in combination with carbidopa/levodopa in patients with Parkinson's Disease over 27 days, and its exploratory phase 2, open label, single arm study that assessed the safety and efficacy of 20 mg oral NE3107 in 18 patients with mild cognitive impairment or mild dementia and 5 patients with moderate dementia over 3 months.

16:13 EDT Middlesex Water CEO Dennis Doll to retire - Middlesex Water president and CEO, Dennis Doll has announced a plan to retire upon turning age 65. Doll's retirement is planned for the later of December 31 or the date when a successor is duly named and on board. He will remain a member of the board through the expiration of his current term in May 2024. A search for Doll's successor is being led by the Compensation Committee of the board of directors in collaboration with Russell Reynolds Associates.

16:11 EDT Zscaler appoints Syam Nair as Chief Technology Officer - Zscaler announced that Syam Nair has been appointed as the company's Chief Technology Officer and EVP of Research and Development. In this role, Nair will be responsible for driving the research and development engines to expand Zscaler's Zero Trust Exchange platform, accelerate AI/ML innovations, and further scale the largest security cloud in the world. Nair will join Zscaler's senior executive team on May 24 . "

16:09 EDT Aspira Women's Health names Torsten Hombeck as CFO - Aspira Women's Health (AWH) announced it has appointed Torsten Hombeck, Ph.D., as Chief Financial Officer, replacing interim CFO Marlene McLennan. Dr. Hombeck brings to Aspira extensive experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings. The change will be effective on June 15. Dr. Hombeck joins Aspira from his role as CFO of Akari Therapeutics ( AKTX) where he raised over $44M during his three year tenure there. His previous positions include Chief Commercial and Strategy Officer and Managing Director at Promethera Biosciences, and Co-Chief Executive Officer and Chief Business Officer at Cytonet where he played an integral role in its acquisition by Promethera. Dr. Hombeck also served as Chief Financial Officer at both Agennix and GPC Biotech. He holds a Masters in Business Administration and a Ph.D. in Finance.

16:07 EDT X4 Pharmaceuticals says mavorixafor treatment reduced annualized infection rate - X4 Pharmaceuticals is hosting a webinar highlighting new data from its global, pivotal, 4WHIM Phase 3 clinical trial of once-daily, oral mavorixafor in individuals with WHIM syndrome. Following the announcement of top-line data from the 4WHIM trial in November 2022, this event focuses on the impact of mavorixafor on the rate, severity, and duration of infections in trial participants. In the trial, mavorixafor treatment resulted in a statistically significant reduction in annualized infection rate versus placebo. In addition, the data showed that the reduction was greater with time on treatment, with participants on mavorixafor experiencing less than one infection per year versus 4.5 for those on placebo; during the second six months of the trial, the difference also achieved statistical significance. During the trial, 29% of those on placebo experienced Grade 3 or higher infections, whereas only 7%, of those on mavorixafor experienced a Grade 3 or higher infection, equating to a 75% reduction in the number of individuals experiencing severe infections. Importantly, the single Grade 3 infection in the mavorixafor treatment arm occurred during the first 3 months of the trial; after 3 months of treatment, there were no serious infections in the mavorixafor-arm, whereas the frequency of severe infections in those on placebo remained unchanged over the 52-week trial period. In the trial, mavorixafor treatment reduced the total duration of infections by more than 70% as compared to placebo, with those on placebo experiencing a mean of seven weeks with infections over the 52-week trial period versus a mean of only two weeks with infections for those treated with mavorixafor. Mavorixafor treatment resulted in a 40% lower total infection score, a metric that combines infection number and severity. Treatment with mavorixafor also resulted in reductions in upper and lower respiratory tract and skin infections compared with those on placebo; participants on placebo required greater medical intervention, with 10 of the 17 participants on placebo requiring treatment with antibiotics over the course of the study, versus 3 of the 14 receiving mavorixafor; and slight improvements in warts were demonstrated both in the mavorixafor and placebo arms. As reported previously, mavorixafor was generally well tolerated in the 4WHIM trial, with no drug-related serious adverse events, no treatment limiting toxicities, and no discontinuations due to safety. Approximately 90% of participants in the trial continued on to receive mavorixafor treatment in the ongoing open-label extension study. A late-breaking abstract of these data was accepted for presentation at the annual meeting of the Clinical Immunology Society, or CIS, taking place May 18-21, 2023 in St. Louis. Dr. In addition, X4 is also announcing that its submitted abstract of these data was accepted for oral presentation at the annual meeting of the European Hematology Association, or EHA, taking place June 8-15 in Frankfurt, Germany.

16:06 EDT Lyft names Brewer as Chief Financial Officer - Lyft (LYFT) announced that Erin Brewer has been named Lyft's Chief Financial Officer, effective July 10. Brewer replaces Elaine Paul, who is leaving Lyft but will remain as an advisor until November 30, 2023. Lisa Blackwood-Kapral, Chief Accounting Officer, will serve as interim CFO until Brewer's start date. Between May 2020 and October 2022, Brewer served as Managing Director Enterprise Finance at Charles Schwab & Co (SCHW) where she led her team through historic client and asset growth, scaling efficiently while retaining the company's renowned focus on serving customers. There is no change to Lyft's previously announced Q2 2023 revenue, Contribution Margin, Adjusted EBITDA and Adjusted EBITDA margin outlook provided on May 4, 2023. The company will report Q2 results in August and plans to release long-term targets in 2023.

16:04 EDT Bunge, Nutrien enter strategic alliance to support U.S. farmers - Bunge (BG) and Nutrien Ag Solutions, the retail division of Nutrien (NTR), announced a strategic alliance and commercial agreement to support U.S. farmers in the implementation of sustainable farming practices that will help increase the development of lower carbon products. The initiative is expected to expand sustainable agriculture across shared supply chains in North America, bringing more whole-acre solutions to food, feed and fuel customers and end-consumers. The initial program will focus on soybeans grown in the regions close to Bunge's crushing facilities in Council Bluffs, Iowa, and Decatur, Indiana, with the opportunity for future expansion to other locations and crops such as corn and wheat. The program is targeting the 2023/2024 crop season and is expected to include practices such as cover crops, reduced tillage, nutrient management and responsible pesticide use.

16:00 EDT Texas Community Bancshares announces stock repurchase program - Texas Community Bancshares, announced that its Board of Directors has adopted a stock repurchase program that will allow the company to repurchase up to 164,842 shares of its outstanding common stock. This number equals approximately 5.0% of shares currently outstanding.

15:03 EDT Juniper appoints new Chief Marketing Officer - Juniper Networks (JNPR) announced that effectively immediately, Jean English has been named Senior Vice President and Chief Marketing Officer. Prior to Juniper, Ms. English served as SVP and CMO of NetApp (NTAP), CMO at Palo Alto Networks (PANW), Global Vice President of Marketing for IBM Cloud (IBM) and, most recently, CMO at Armis Security, Juniper noted.

14:01 EDT Audacy trading halted, news pending

12:53 EDT Prometheus, Seagen slip after FTC sues to block Horizon acquisition - Shares of Prometheus (RXDX) are down about 1% to $192.78 in afternoon trading while those of Seagen (SGEN) are down about 5% to $189.73 after the Federal Trade Commission filed a complaint seeking to block Amgen's (AMGN) proposed acquisition of Horizon Therapeutics (HZNP). Merck (MRK) is slated to close its acquisition of Prometheus for $200 per share by Q3, while Pfizer (PFE) previously announced an agreement to acquire Seagen for $229 per share.

12:05 EDT Penn State, onsemi sign MOU to boost silicon carbide research in U.S. - onsemi and Penn State announce the signing of a memorandum of understanding towards an $8 million strategic collaboration which includes the establishment of the onsemi Silicon Carbide Crystal Center at Penn State's Materials Research Institute (MRI). onsemi will fund SiC3 with $800k per year over the next 10 years. In addition to conducting SiC research at SiC3, Penn State and onsemi will raise awareness about the increasing demand for tech jobs in the semiconductor industry. This is part of their efforts to enhance the share of U.S. semiconductor manufacturing. They also will partner on workforce development initiatives such as internship and cooperative programs and include SiC and wide bandgap crystal studies in Penn State's curriculum. The relationship with Penn State is part of onsemi's commitment to promoting STEAM education, ranging from helping K-12 students in underserved communities to university collaborations that support the development of the workforce for today and the future.

12:02 EDT Mid-Southern: ISS, Glass Lewis recommend voting against IB firm engagement - Mid-Southern Bancorp issued a letter to the company's stockholders in connection with the company's annual meeting of stockholders. The letter says in part: "In connection with the annual meeting of stockholders, the Board of Directors of Mid-Southern Bancorp is proud to announce that leading independent proxy advisory firms, Glass Lewis & Co. and Institutional Shareholder Services, Inc., recently recommended that stockholders vote AGAINST the stockholder proposal recommending the engagement of an investment banking firm to sell the Company. We urge you to vote AGAINST the stockholder proposal by signing, dating and returning the proxy card for the Annual Meeting. The Board of Directors believes that the stockholder proposal is unnecessary and not in the best interests of the Company or its stockholders. We believe that actively seeking a buyer would be a distraction to the Company and may damage our reputation with our clients by creating uncertainty. In addition, due to the current state of volatility in the capital and credit markets and uncertainty with respect to the health of the U.S. banking system, we believe that the current market is an especially inopportune time to explore a sale of the Company."

12:00 EDT Sea Limited falls -15.7% - Sea Limited is down -15.7%, or -$13.80 to $74.27.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 7.5% - Daily S&P Biotech Bear 3x Shares is up 7.5%, or 95c to $13.61.

12:00 EDT Alerian Midstream Energy Index rises 1228.9% - Alerian Midstream Energy Index is up 1228.9%, or $445.42 to $481.67.

11:55 EDT Baosheng Media Group Holdings Ltd trading resumes

11:52 EDT SAP announces share repurchase program of up to EUR 5B - At SAP Sapphire in Orlando, SAP SE announced an update of its mid-term financial Ambition 2025 as well as a new share repurchase program with a volume of up to EUR 5B, the company reported in a press release. "Today's Ambition 2025 update demonstrates SAP's momentum in this new phase of our transformation. Our strong, resilient cloud growth drives accelerating total revenue and operating profit growth. We are increasing our total revenue ambition for continuing operations by close to EUR 4 billion, expect significant further acceleration of revenue growth towards 2025 and beyond," said Christian Klein, CEO.

11:49 EDT Horizon Therapeutics responds to FTC's action to block acquisition by Amgen - Horizon Therapeutics (HZNP) issued the following statement in response to the FTC's complaint seeking to block Amgen's (AMGN) proposed acquisition of the company: "This acquisition has the potential to accelerate the availability of important rare disease medicines to more patients worldwide. The FTC's complaint impacts patients and is rooted in a theory about potential future "bundled" contracts with payors and not competitive overlap concerns. Horizon does not and has no plans to bundle any of its rare disease medicines. It is imperative that we continue to advocate for access to innovative treatments for patients who may benefit, particularly in diseases with significant unmet needs, and the proposed transaction with Amgen is part of that mission. We firmly believe in the benefits of this acquisition and intend to work with the court on a schedule that would allow the transaction to close by mid-December."

11:35 EDT Texas AG sues Hyatt Hotels over 'true price' of hotel rooms - Attorney General Paxton filed a lawsuit against Hyatt Hotels for "violating Texas consumer protection laws by marketing hotel rooms at prices that were not available to the public as advertised." "Hyatt implemented this practice by charging consumers mandatory and unavoidable fees-such as resort fees, destination fees, or amenity fees-in addition to daily room rates. Even when these fees were eventually disclosed, they were done so in a manner that was unlikely to alert consumers that the initial rate that attracted them was not, in fact, the actual price of the room," the AG's office said. "Hyatt's lack of transparency regarding hotel room prices has misled consumers and violated Texas law," said Attorney General Paxton. "These deceptive practices enabled Hyatt to advertise lodging at artificially low rates, and it must end immediately. I will not stand by while Texas consumers are taken advantage of by Hyatt, or by any hotel chain that tries to get away with charging illegal hidden fees." Reference Link

11:34 EDT Amgen 'disappointed' in FTC's decision to block Horizon Therapeutics deal

11:33 EDT Amgen responds to FTC action on proposed acquisition of Horizon Therapeutics - Amgen (AMGN) issued the following statement in response to the U.S. Federal Trade Commission's complaint seeking to block the company's proposed acquisition of Horizon Therapeutics (HZNP): "Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very serious rare diseases in the U.S. and around the world. We have been working cooperatively over the past several months to address the questions raised by the FTC's investigative staff and believe we have overwhelmingly demonstrated that this combination poses no legitimate competitive issues. The medicines offered by Amgen and Horizon generally treat different diseases and patient populations, and there are no overlaps of competitive concern. The FTC's claim that Amgen might "bundle" these medicines [offer a multi-product discount] at some point in the future is entirely speculative and does not reflect the real world competitive dynamics behind providing rare-disease medicines to patients. And we committed that we would not bundle the Horizon products raised as issues; however, the Commission still decided to pursue this path. Furthermore, we are unaware of any prior acquisition that has been blocked under a bundling theory. We firmly believe in the benefits of this acquisition and intend to work with the court on a schedule that would allow the transaction to close by mid-December."

11:08 EDT ServiceNow announces launch of Finance, Supply Chain Workflows - ServiceNow announced a major expansion of the ServiceNow portfolio, applying intelligent automation to business-critical processes, with the launch of Finance and Supply Chain Workflows. These new AI-powered workflows help finance, supply chain, and procurement leaders reduce costs and accelerate time to value, while improving user experience, ServiceNow said.

10:57 EDT FTC sues to block Amgen, Horizon Therapeutics deal on monopoly concerns - The Federal Trade Commission said it is seeking to block Amgen (AMZN) from acquiring Horizon Therapeutics (HZNP), saying the deal "would allow Amgen to leverage its portfolio of blockbuster drugs to entrench the monopoly positions of Horizon medications used to treat two serious conditions, thyroid eye disease and chronic refractory gout." The FTC filed a lawsuit in federal court to block the transaction, saying "it would enable Amgen to use rebates on its existing blockbuster drugs to pressure insurance companies and pharmacy benefit managers into favoring Horizon's two monopoly products - Tepezza, used to treat thyroid eye disease, and Krystexxa, used to treat chronic refractory gout." Neither of these treatments have any competition in the pharmaceutical marketplace, the FTC noted. "Given how central protecting and growing Tepezza and Krystexxa monopoly revenues are to the deal valuation Amgen calculated for Horizon, Amgen has strong incentives post-acquisition to raise Tepezza and Krystexxa rivals' barriers to entry or dissuade them from competing as aggressively if and when they gain FDA approval," the agency argues. Shares of Horizon Therapeutics are down 18% to $91.77 in morning trading while Amgen is down 1% to $231.71. Reference Link

10:40 EDT FTC files suit to block Amgen acquisition of Horizon Therapeutics

10:08 EDT Sony, Astellas Pharma enter collaborative research agreement - Sony Corporation (SONY) and Astellas Pharma (ALPMY) announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate platform in oncology based on Sony's unique polymeric material, "KIRAVIA Backbone." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which conjugate antibodies and drugs is considered to be a key to the development of a better-performing ADC. This collaborative research leverages the flexibility in design and resulting properties such as high capacity and solubility of KIRAVIA Backbone as a linker of ADC, to effectively deliver anti-cancer drugs to targeted cells in a stable manner, aiming to further enhance therapeutic efficacy by achieving high Drug-to-Antibody Ratio, etc. The two companies jointly began exploratory research of new linker technology aimed at creating a new ADC platform in July 2022, and the expected profile was obtained in feasibility studies using human cancer cells. Under this agreement, Sony and Astellas will jointly develop and optimize a new ADC platform using the KIRAVIA Backbone as a linker. In addition, Astellas will conduct non-clinical trials of development candidates. Furthermore, in order to build a drug discovery platform not limited to ADC, the two companies have agreed to continue discussions on expanding research partnerships to create new value by combining Sony's cutting-edge technology with Astellas' renowned pharmaceutical capabilities.

10:06 EDT Auradine raises $81M in Series A financing - Auradine raised $81 million in its initial round of funding. The Series A funding was led by Celesta Capital and Mayfield, with Sriram Viswanathan of Celesta and Navin Chaddha of Mayfield joining the Auradine board. Other investors included Marathon Digital Holdings, Cota Capital, DCVC, and Stanford University.

10:03 EDT Cognizant, Cleo form global cloud integration partnership - Cleo has entered into a global partnership with Cognizant to power the Cognizant Cloud Integration Brokerage for the enterprise market. This new B2B platform-as-a-service solution, which comprises elements from Cleo's flagship offering, the Cleo Integration Cloud, will be named "CCIB, powered by Cleo," and provides B2B managed services with built-in, scalable infrastructure on the cloud. Cognizant professionals have been trained in the deployment and management of Cleo's enterprise integration technology, enabling end-user customers to immediately benefit from the combined solution directly and expeditiously.

10:02 EDT Coya Therapeutics Inc trading halted, volatility trading pause

10:00 EDT Sea Limited falls -13.3% - Sea Limited is down -13.3%, or -$11.73 to $76.33.

10:00 EDT James Hardie rises 7.1% - James Hardie is up 7.1%, or $1.62 to $24.48.

10:00 EDT Alerian Midstream Energy Index rises 1250.8% - Alerian Midstream Energy Index is up 1250.8%, or $453.37 to $489.61.

09:59 EDT Chinook Therapeutics weakness attributed to short call - Shares of Chinook Therapeutics are down $3.74, or 16%, to $19.66, which is being attributed by traders to the circulation of a short report targeting the company.

09:50 EDT Modine Manufacturing to expand Europe production to serve heat pump market - Modine Manufacturing is expanding operations at its current location in Sremska, Serbia, to meet growing demand from the heat pump market in Europe, the company announced. When complete later this year, the new facility will be a dedicated manufacturer of coils for commercial and residential heat pump applications, Modine said in a statement. "We are excited to expand our manufacturing operations in Serbia to serve our key customers in Europe and beyond," said Eric McGinnis, President, Climate Solutions. "The market for heat pumps is experiencing tremendous growth in Europe and we want our manufacturing centers closer to our key customers. Serving them with best-in-class heat transfer technology that reduces energy consumption and lowers harmful emissions is one way Modine lives out our purpose of engineering a cleaner, healthier world."

09:47 EDT Maravai LifeSciences trading resumes

09:47 EDT Eloxx Pharmaceuticals trading resumes

09:47 EDT Ducommun falls -13.5% - Ducommun is down -13.5%, or -$6.53 to $41.89.

09:47 EDT Nu Holdings rises 10.8% - Nu Holdings is up 10.8%, or 66c to $6.75.

09:42 EDT Maravai LifeSciences trading halted, volatility trading pause

09:36 EDT Ohmyhome Ltd trading resumes

09:31 EDT Ohmyhome Ltd trading halted, volatility trading pause

09:23 EDT IBM to acquire Polar Security; terms not disclosed - IBM announced that it has acquired Polar Security, which it describes as "an innovator in technology that helps companies discover, continuously monitor and secure cloud and software-as-a-service application data - and addresses the growing shadow data problem." IBM plans to integrate Polar Security's DPSM technology within its Guardium family of data security products, IBM said. Financial terms of the deal have not been disclosed.

09:21 EDT Ohmyhome signs MOU for acquisition of Singapore property management firm - Ohmyhome announces the signing of a non-legally binding Memorandum of Understanding for the potential acquisition of a leading tech-enabled property management company in Singapore. Over 300,000 families in Singapore reside in condominiums, and there are close to 20,000 additional units to be completed by the end of 2023. Residents interact regularly with the property management company of their condominium development for the needs of facilities booking, guest registration, moving and renovation approvals. Current processes are largely paper-based, heavily dependent on manpower which leads to inefficient communication and service delivery. Upon successful closing of the transaction, thousands of residents in Singapore will immediately be able to access Ohmyhome's latest homeowner dashboard, Homer AI, for quality information and content on their home value and latest property trends, as well as Ohmyhome's quality services such as brokerage, renovation, cleaning, and handyman services directly on their fingertips. The streamlined services and strong vertical integration will provide additional value-add to the property development company in securing more projects for future growth. Post-integration of the technologies and operations of both companies will further bolster Ohmyhome's suite of one-stop-shop services to both property developers and residents in Singapore and Southeast Asia. The transaction is subject to the customary closing conditions and completion of regulatory review.

09:14 EDT Issuer Direct releases AImee AI writing assistant, recommendation engine - Issuer Direct Corporation has released "AImee," it's AI-Writing Assistant & Recommendation Engine, which will empower clients to generate more powerful stories, engaging content, and targeted messaging. AImee will launch next month in beta for select customers, with an eye on commercial launch in the third quarter. The company expects to see subscription revenue expansion from this new add-on, as well as a further contribution to customer growth in the coming quarters. As Issuer Direct further invests in elevating itself above its competitors, the Company is committed to providing and growing its comprehensive communication offerings on one central platform.

09:11 EDT Imperial Petroleum regains compliance with Nasdaq minimum bid price requirement - IMPERIAL PETROLEUM announced that it has received a letter from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The letter noted that, as a result of the closing bid price of the Company's common stock having been at $1.00 per share or higher for at least ten consecutive trading days, from April 28, 2023 through May 11, 2023, the Company has regained compliance with Nasdaq's Listing Rule 5550(a)(2).

09:10 EDT Avalon Acquisition announces date of special meeting of stockholders - Avalon Acquisition announced that it has set June 6, 2023 as the meeting date for the special meeting of stockholders to approve the previously announced business combination with The Beneficient Company Group and related proposals. At the Special Meeting, Avalon's stockholders will be asked to approve the Business Combination and other such proposals as disclosed in the definitive proxy statement/prospectus relating to the Business Combination. Holders of AVAC Class A common stock and Class B common stock at the close of business on the record date of May 10, 2023 are entitled to notice of the Special Meeting and to vote at the Special Meeting. The closing of the Business Combination is subject to approval by Avalon's stockholders and the satisfaction or waiver of other customary closing conditions. If the proposals at the Special Meeting are approved, Avalon anticipates that the business combination will close shortly thereafter, subject to the satisfaction or waiver of all other closing conditions. Upon the closing of the Business Combination, it is expected that Beneficient will be a publicly listed company, and its Class A common stock, Series A convertible preferred stock and warrants are expected to begin trading on the Nasdaq under the symbols BENF, BENFP and BENFW, respectively.

09:08 EDT MeiraGTx announces presentation of nine posters at ASGCT 2023 - MeiraGTx announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy, ASGCT, 2023 Annual Meeting, which is being held from May 16-20, 2023, in Los Angeles, CA. "Our presentations at this year's ASGCT Annual Meeting reflect the significant progress made in our novel gene and cell therapy platforms, including promoter discovery and development, manufacturing technology as well as several in vivo proof of concept efficacy studies using our riboswitch platform," said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. "Our riboswitch gene control platform allows us to precisely control the expression of any gene in a tight dose response to oral small molecules and to control gene expression to a very high dynamic range, from undetectable at baseline to levels generally greater than the maximum expression of the unregulated vector expressing the same gene. Importantly, we are presenting data on in vivo dose dependent efficacy of our riboswitch in animal models. We demonstrate efficacy of vector-delivered human growth hormone, rescuing B.little mice by controlling hGH expression in a periodic fashion with an oral small molecule, and data demonstrating control of tumor burden by regulating anti-HER2 antibody in tight dose response to an orally dosed small-molecule inducer." Dr. Forbes continued, "We are also presenting data demonstrating precise regulation of CAR levels on CAR-Ts, with the unprecedented ability to intermittently switch CAR on to low receptor density levels, which results in increased CAR-T potency, decreased exhaustion markers and increased safety when directly compared to CAR-T with constitutively expressed CAR. These three examples, along with data on our promoter discovery platforms presented at ASGCT, provide support for the broad applicability of our gene regulation technology across multiple therapeutic targets for gene and cell therapy."

09:08 EDT Zoom Video partners with Anthropic to expand federated approach to AI - Zoom announced a strategic partnership with and investment in Anthropic, an AI safety and research company working to build reliable, interpretable, and steerable AI systems. The collaboration with Anthropic will further bolster Zoom's federated approach to AI by allowing Anthropic's AI assistant, Claude, to be integrated with Zoom's platform, starting with Zoom Contact Center. "Anthropic's Constitutional AI model is primed to provide safe and responsible integrations for our next-generation innovations, beginning with the Zoom Contact Center portfolio. With Claude guiding agents toward trustworthy resolutions and powering self-service for end-users, companies will be able to take customer relationships to another level," said Smita Hashim, chief product officer for Zoom. "Partnering with Anthropic also furthers our commitment to providing customers with our federated approach to AI, optimized to deliver outstanding customer experience outcomes. Additionally, with our investment, we are advancing leading-edge companies like Anthropic and helping to drive innovation in the Zoom ecosystem and beyond." Zoom's federated approach to AI leverages its own proprietary AI models, along with those from leading AI companies - such as Anthropic - and select customers' models. With this flexibility to incorporate multiple types of models, Zoom can provide the most value for its customers' diverse needs. Zoom will be able to customize these models to perform better for a customer, based on their specific business needs.

09:07 EDT 3M and Svante sign development agreement for carbon dioxide removal products - 3M is working with Svante Technologies to develop material that can trap carbon dioxide found in the atmosphere and permanently remove it. 3M Ventures, the venture capital arm of 3M, recently participated in Svante's Series E fundraising round, which raised $318M to accelerate the manufacturing of Svante's carbon capture and removal technology. Svante has developed a process for coating solid sorbents onto laminate sheets and stacking into high-performance filters, which are available for both industrial point-source capture and for direct air capture. Letourneau says Svante's technology can be applied to 85% of the total carbon capture and removal segment.

09:07 EDT NewtekOne hires Price as Chief Financial Officer - NewtekOne announced that it has hired Mr. M. Scott Price as Chief Financial Officer, CFO, of the Company, effective May 16, 2023. Price comes to NewtekOne with over 17 years' experience in the financial services industry with specific focuses on, and an extensive background in, banking and accounting. Most notably, Scott spent close to a decade at IBERIABANK Corporation in the role of Executive Vice President, Chief Accounting Officer and Corporate Controller.

09:06 EDT Galaxy Gaming, Evolution extend licensing agreement for 10 years - Galaxy Gaming announced that is has signed an agreement with Evolution Group for the licensing of Galaxy table game content across their portfolio of studios. The agreement runs for ten years and strengthens Evolution's collection of online table games. This agreement builds upon the existing success of Galaxy's world-famous table game and side bets available now on Evolution products. "Extending our long-standing partnership with Evolution aligns with our focus to deliver the best table game content to everyone, everywhere," shared Todd Cravens, President and CEO of Galaxy Gaming. "Evolution continues to develop a robust catalogue of top-performing and innovative titles. We are delighted to continue to be a part of this impressive product portfolio and thrill their players with our world-famous games."

09:04 EDT Pushpay announces Everygift system - Pushpay announced two innovative offerings to expand its leadership in church giving. The Company introduces Everygift-a proprietary system of automated features to help churches reduce failed payments, increase payment reliability, and grow generosity-in addition to a new partnership with Engiven, the leading cryptocurrency donation platform.

09:01 EDT Abbott announces FDA approval of spinal cord stimulation devices - Abbott announced that the U.S.FDA has approved its spinal cord stimulation devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain.

08:51 EDT Ispire Technology expects cash to fund operations in next 12 months - As of March 31, 2023, and prior to the closing of its initial public offering, Ispire had cash and cash equivalents of $24.0 million and working capital of $5.2 million. The Company believes that its current cash and cash flows provided by operating activities, and the net proceeds from the initial public offering will be sufficient to meet its working capital needs in the next 12 months.

08:48 EDT Carpenter Technology highlights priorities, financial goals at Investor Day - Carpenter Technology Corporation will hold an investor event covering the company's strategic priorities and financial goals. The presentation will also be broadcast live via webcast. "Carpenter Technology is at an inflection point, with the opportunity to realize meaningful, profitable growth", said Tony Thene, President and CEO. "We participate in high growth, high value markets, including the aerospace and defense and medical end-use markets. And we have the world-class capabilities and assets that deliver the materials solutions our customers need. Operating in a strong demand environment with our unique portfolio of material solutions, we are well-positioned to accelerate growth. Primarily driven by higher prices, an improving product mix and increasing volumes, we see a path to double operating income from fiscal year 2019 levels by fiscal year 2027. This operating income growth will deliver meaningful cash flow over the next several years, driving further value to our shareholders." In addition to providing insight into the business, the Company will provide detail on its stated goal to double fiscal year 2019 adjusted operating income by fiscal year 2027: Specialty Alloys Operations segment expected to exceed 20 percent adjusted operating income margins on net sales excluding surcharges of approximately $2.2 billion to 2.4 billion in fiscal year 2027. Performance Engineered Products segment expected to reach adjusted operating income margins of 13-15 percent on $570 million to $610 million of net sales excluding surcharges in fiscal year 2027. Overall, expected to generate $400-600 million in cumulative adjusted free cash flow between fiscal year 2024 and fiscal year 2027.

08:46 EDT Conduent announces $75M share repurchase program - Conduent Incorporated announced that its board of directors has approved a share repurchase program of up to $75 million of the Company's common stock over the next three years.

08:41 EDT Baidu aims to continue enhancing margins across all major operations - Comments taken from Q1 earnings conference call.

08:40 EDT Newell Brands cuts quarterly dividend to 7c per share from 23c - Newell Brands "announced that its Board of Directors, together with the management team, updated the company's dividend policy, reducing the quarterly dividend to $0.07 per share. The dividend is payable June 15, 2023 to common stockholders of record at the close of business on May 31, 2023."

08:39 EDT NetSol Technologies announces solution AFS Ascent for Ikano Bank - NETSOL Technologies announced the go-live of its next-generation solution NFS Ascent for Ikano Bank - a Swedish bank operating across the Nordic and European regions. NETSOL's NFS Ascent and suite of digital solutions are being implemented on the Cloud to support Ikano Bank's lending to businesses. "The partnership with Ikano Bank is a significant project for NETSOL Europe representing the largest multi-country roll-out of our premier platform NFS Ascent. This engagement contributes to a multi-million-euro partnership for the Nordic region and beyond," said Asad Ghauri, President Asia-Pacific and Group MD Europe, NETSOL Technologies, Inc. "This has been a very exciting journey with more milestones to achieve as Ikano Bank expands into the wider European Economic Area."

08:38 EDT Cellebrite, The Exodus Road provide digital intelligence technology to NBI - Cellebrite and The Exodus Road announced that they are providing digital intelligence technology to ensure the National Bureau of Investigations, NBI, Anti-Human Trafficking Division in the Philippines has the capacity to accelerate justice in cases of exploitation. "In our commitment to stop human trafficking in the Philippines and around the world, we actively pursue technologies and other tools that can aid our law enforcement partners as they combat the increasingly digital world of trafficking," said Matt Parker, Co-Founder, and Chief Strategist at The Exodus Road. "We continually see Cellebrite's digital intelligence technology directly impacting our partners' ability to expose exploitation, free survivors and prosecute traffickers. Cellebrite's provision of their most sought-after solutions to NBI in the Philippines will not only accelerate justice but will also protect the integrity of NBI's work and ours by taking the stand in human-trafficking cases as a third-party voice and leader in digital forensics."

08:36 EDT QSAM Biosciences, RLS announce clinical, commercial supply agreement - QSAM Biosciences and RLS announced a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam, a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children. "We believe the short half-life of Samarium-153 with respect to patient exposure, toxicity and tolerability makes it an ideal drug to treat bone cancers. The ability to meet the potential demand requires a pharmacy network capable of preparing and timely delivering patient doses for administration," said Douglas R. Baum, CEO and co-founder of QSAM. "The RLS network of 31 radiopharmacies across 18 states adds significant geographic coverage and infrastructure to our supply chain, along with an unprecedented level of on-the-ground expertise and credibility as the only accredited radiopharmacy network in the country. Choosing RLS as a partner will not only bolster our current and near-term clinical trials, but it may also provide the initial groundwork for eventual commercial supply and distribution."

08:34 EDT Milestone Scientific commences sales of CompuFlo Epidural - Mlestone Scientific announced that it has commenced sales of CompuFlo Epidural disposables into The Pain and Rehabilitation Medical Group in Torrance, California. Adoption of the technology by this clinic follows a successful evaluation process by its founder, Dr. Fabian Proano, an interventional pain medicine physician, who is board-certified by the American Board of Anesthesiology in both anesthesiology and pain medicine.

08:29 EDT Ra Medical Systems decides to close laser catheter business - Ra Medical Systems announced the first corporate update since the merger of the private company Catheter Precision, Inc. into the public company Ra Medical Systems. Catheter Precision continues to operate as a wholly owned subsidiary of RMED, which operates as the parent. The RMED board of directors, as part of its governance commitment, last month established a committee for examining a transition at the CEO level. Mr. David Jenkins, the Company's Executive Chairman of the Board, is serving as Interim CEO until a full-time replacement is named. Jenkins said, "Since the time of the merger in January, we have analyzed our opportunities and resources and have affirmed our decision to focus on Catheter Precision's cardiac electrophysiology technologies and markets. As such, we have decided to close the laser catheter business of Ra Medical. Although Ra Medical had a 510(K) FDA approval, an ongoing clinical trial nearing its endpoint, and an intellectual property portfolio, we believe that the target market required a broader product offering which entailed further research and development before bringing its products to market. Therefore, our decision was made to allocate our limited resources to the cardiac electrophysiology field, with a team and products in place. We believe these changes and others are in strong alignment with cash management and the overall shareholder interest."As part of the transition, and to appropriately match expenditures to the size of the company, several notable changes have been made. The facility in Carlsbad, California was closed, and the leases were terminated. All employees associated with the manufacture of the laser catheter were terminated. Legal representation has been changed from a costly international firm to a smaller regional firm. Better cash management on excess funds has been instituted. Will McGuire, RMED's previous CEO, resigned as of the end of April. The part-time Acting CFO has been replaced with a full-time permanent CFO. The board of directors has been reduced from five to four directors, and director pay has been reduced. The salary and bonus of the acting CEO is limited to $300,000 annually. The company has brought in $8 million in new funding, so that as of May 1, 2023, Ra Medical had approximately $11 million on hand, which is prior to payment of Mr. McGuire's severance payment in May. Management believes these cash resources will last into 2024. In addition to these above changes, Ra Medical has made additional investments into the electrophysiology business, with several highlights to share: Five new area sales representatives and three additional clinical support specialists were hired, onboarded, and fully trained as of April 1, 2023. This has resulted in over 70 new target accounts for our VIVO product on May 1, 2023, and over 20 target accounts for our recently launched LockeT product, all in the US. Catheter Precision launched LockeT, a brand-new closure device, which is a Class I device labeled for suture retention. This product is not only applicable to electrophysiology procedures, but also structural heart procedures, percutaneous pacemaker implants, and vascular surgery procedures. The VIVO European registry has almost completed enrollment, now having enrolled 125 patients. New clinical studies for both VIVO and LockeT will begin later this year. Catheter Precision will attend the Heart Rhythm Society annual scientific sessions, to be held May 19-21, where our products will be on display in the exhibit hall, including VIVO and the new LockeT closure device. The company plans to file a Form 12b-25 Notification of Late Filing on May 16, 2023, and to file the 10-Q for the first quarter ending March 31, 2023, by May 22, 2023, and will release first quarter financial information at that time.

08:24 EDT Netcoins Canada to launch Staking services from BIGG Digital - BIGG Digital Assets, owner of Netcoins, and Blockchain Intelligence Group announce that Netcoins Canada will be launching Staking services for Ethereum. Netcoins received full approval to offer Crypto Staking Services in the Canadian market on May 15, 2023, from the British Columbia Securities Commission, under its restricted dealer license. Netcoins has been a registered and compliant restricted dealer since 2021.BIGG CEO, Mark Binns, commented, "Netcoins is now 1 of only 3 regulated crypto staking platforms in Canada, and this approval is a big step forward for our platform and future. This shows our high level of engagement with the Canadian regulators and our maturity - we have nearly 10 years of experience in the Canadian crypto industry. With staking, we look forward to welcoming new customers to the platform on the back of this substantial new offering."

08:21 EDT Homology Medicines announces six presentations on gene editing, therapy - Homology Medicines announced today six presentations supporting its gene editing, gene therapy and GTx-mAb programs at the American Society of Gene & Cell Therapy 26th Annual Meeting, including the first data from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These preclinical data demonstrated that a one-time administration of HMI-104 resulted in sustained expression of C5 monoclonal antibody levels, supporting the use of a one-time vectorized approach for PNH to enable continuous antibody production. "Given the severity of PNH, which is a rare, acquired blood disorder, and the unmet need associated with chronically administered available therapies, HMI-104 could provide an important new one-time approach," said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. "We are continuing to advance HMI-104 through IND-enabling studies as well as progress our GTx-mAb platform for ocular diseases, with potential for other indications with larger patient populations."

08:19 EDT Blink Charging commissions first battery to store energized DC - Blink Charging announced the commissioning of their new integrated battery storage and DCFC chargers unit that will integrate with four Blink EV chargers at the Southport Plaza in Philadelphia, PA. This marks the first battery storage energized DCFC chargers to go online in the state and a milestone for EV charging resiliency. The new state-of-the-art battery energy storage system efficiently stores energy onsite then provides that power to EV drivers when they need it most. This allows the energy to be captured during off-peak usage times when electricity prices are lowest and releases that energy to charge EVs during peak-usage times when electricity prices are higher, to offset the costs of demand fees. "This innovative battery storage technology is an exciting innovation to EV charging and we're proud to launch this unit in Pennsylvania as we look ahead to other regions where this technology can be used," said Brendan Jones, President and Chief Executive Officer of Blink Charging. "We have made it a goal at Blink to address the concerns of EV drivers, such as grid dependency, and work with our world-class engineers and stakeholders to develop solutions. This battery storage unit certainly does that."

08:18 EDT Microchip announces two new reclocker/redriver devices - To provide long-distance and reliable USB solutions to the market, Microchip announces two new reclocker/redriver devices. The automotive EQCO510 and industrial EQCO5X31 reclocker/redriver devices extend USB coverage up to 15 meters for maximum reach and are compatible with the USB 3.2 Generation 1 SuperSpeed protocol. The EQCO510 and EQCO5X31 are USB reclocker/redriver devices that can send high-speed data signals with a rate of 5 Gbps in both directions. The reclocking feature includes a bit-level Clock-Data Recovery that is used to restore signal timing and prevent jitter accumulation. The redriving feature restores the levels and shape of the signal being driven into the next segment such as a cable or printed-circuit board trace, thus compensating for signal degradation due to cable attenuation.

08:17 EDT FOREWARN partners with Gulf Coast MLS - FOREWARN announced that Gulf Coast MLS has contracted to make FOREWARN services available for the 2,200+ Participants and Subscribers they serve throughout Mobile and the surrounding area to promote proactive real estate agent safety.

08:16 EDT Solid Biosciences to present AVB-202 data at ASGCT annual meeting - Solid Biosciences will present positive preclinical data from studies of AVB-202, the company's gene therapy candidate for the treatment of Friedreich's Ataxia. Grace Pavlath, Ph.D., Vice President, Research at Solid, will present the data in an oral session at 4:45 pm PDT on May 18 at the American Society of Gene and Cell Therapy 2023 Annual Meeting, Los Angeles, May 16-20. Key highlights from the AVB-202 presentation at ASGCT include: AVB-202 rescued cardiac function and extended survival in a mouse model of FA. Data from studies in this model demonstrated dose-dependent increases in FXN protein expression. Results of a six-month safety study in non-human primates using dual routes of administration demonstrated a favorable safety profile. NHP studies also showed that dual IV/IT administration of AVB-202 led to robust FXN protein expression in target tissues, including the heart and CNS. In addition to Dr. Pavlath's oral presentation on AVB-202, Solid will present five abstracts relating to the company's AAV manufacturing methods and quality assurance assays. Brian Collins, Ph.D., Senior Vice President at Solid, also will deliver an invited talk in a session on Comparability Challenges for Chemistry, Manufacturing and Controls.

08:14 EDT Mullen announces first Class 3 vehicle demonstration delivered to Randy Marion - Mullen Automotive announces the first Class 3 demonstration vehicle has been delivered to Randy Marion Automotive in North Carolina. The Mullen THREE is priced at $68,500 and includes an estimated 130-mile range, 5,800 lb payload, and capability of carrying a 14 ft box with over 1,000 cubic feet of cargo capacity. "Randy Marion Automotive Group is a great dealer partner with pent-up demand for cab chassis products," said David Michery, CEO and chairman of Mullen Automotive. "We know our Class 3 will be a great product when it hits the market. We look forward to getting the customer feedback prior to our start of production this summer."

08:13 EDT Trio Petroleum announces HV-1 Well confirmed major oil, gas accumulation - Trio Petroleum announced that its HV-1 well has confirmed that there is a major accumulation of oil and gas in the Presidents Field in its South Salinas Project located in Monterey County, California.The HV-1 well is a two-mile step-out from Trio's HV-3A discovery well that found high-quality, mid-gravity oil at depths between 3,750 to 5,100 feet. The HV-1 well drilled through approximately 1,800 feet of the Monterey Formation with major indications of oil and gas prior to reaching total depth at 6,631 feet. The company is currently running well casing from surface to total depth to properly complete the well, and is commencing its evaluation of the well data collected. Frank Ingriselli, Trio's Chief Executive Officer, commented "We are very excited and pleased with our discovery of oil and gas at the HV-1 well and with the positive impact that we expect this well will have on Trio's future and our commitment to grow shareholder value. We plan to put the HV-1 well on production after we finalize completion operations and our evaluation of the new data we are acquiring from the well, after which we will have a better understanding of production rates, which we plan to announce when available."

08:11 EDT Immutep says FDA 'supportive' of registration trial to evaluate efti in NSCLC - Immutep received positive feedback from the US Food and Drug Administration, regarding the Company's late-stage clinical development plans for its first-in-class soluble LAG-3 protein and MHC Class II agonist, eftilagimod alpha, for the treatment of 1st line non-small cell lung cancer. The FDA is supportive of a registrational trial to evaluate efti in combination with an anti-PD-1 therapy based on the encouraging data from the Phase II TACTI-002, Part A in 1st line NSCLC patients, no matter their level of PD-L1 expression, presented in a late-breaking oral abstract presentation at the 37th Annual Society of Immunotherapy of Cancer Meeting in November 2022. Among the items discussed at the meeting were the toxicological package and general aspects of the trial design, including statistics and potential patient population with a focus on 1st line NSCLC patients with a Tumor Proportion Score PD-L1 of greater than1% for which efti plus pembrolizumab has already received Fast Track designation. This trial will be named TACTI-004.

08:09 EDT FMC Corporation and Syngenta partner for weed control technology - FMC Corporation and Syngenta Crop Protection announced an agreement to bring to market a breakthrough technology to control weeds in rice in Asia. The new active ingredient, tetflupyrolimet, was discovered and developed by FMC with support from Syngenta for development in rice. Under the agreement, FMC and Syngenta both will bring tetflupyrolimet-based products to key rice markets in Asia. FMC will register and commercialize tetflupyrolimet, as well as a broad array of tetflupyrolimet formulations for rice throughout Asia. In the China rice market, FMC will focus on mixtures only. Syngenta will register and commercialize the compound and an array of products in China for the rice market, while offering mixtures for use on rice in India, Vietnam, Indonesia, as well as in Japan and South Korea. Syngenta will also commercialize the compound for rice in Bangladesh. In addition, FMC will register and commercialize tetflupyrolimet and a full portfolio of tetflupyrolimet formulations in markets globally for rice and other crops.

08:09 EDT Equus II Inc forms Morgan E&P as new oil ,as subsidiary - Equus Total Return announced the formation of a new wholly-owned subsidiary, Morgan E&P. Morgan will focus on the acquisition, development and operation of oil and gas assets with a particular emphasis generally in the Bakken area of North Dakota. John Hardy, Morgan's CEO, has brought on three seasoned oil and gas executives with over 70 years of combined experience. Brian McNiell has been appointed as Morgan's President, bringing over 25 years of experience focused on capital raising, investments and the management of operating companies. Prior to this, Brian served for eight years as President and Senior Managing Director of Mancos Resources Corp. making direct investments and providing M&A services in the infrastructure and natural resource space. J. Carlo Limchuatuan has been appointed as Morgan's Chief Operating Officer, bringing over 25 years of experience focused on investing, advising and operating in a variety of industries, primarily related to energy and energy infrastructure. Clarence K. Wong has been appointed as Morgan's Senior Vice President, Operations and Engineering, bringing over 25 years of experience as a chemical, mechanical and process engineer with experience in the upstream, midstream, downstream and renewable segments of the energy value chain.

08:07 EDT Clever granted Brazilian GMP certification for cannabis project by ANVISA - Clever Leaves announced that the Company has received the Brazilian GMP certification by ANVISA, the Brazilian Health Regulatory Agency, to manufacture cannabis products for Brazilian patients. Similar to the strict standards of the EU-GMP certification, ANVISA's Brazilian-GMP certification ensures that patients receive the highest quality of medicine by preventing cases of product contamination, variations in compounds concentrations, mix-ups, incorrect labeling, and more. The certification is required for the manufacturing and commercialization of cannabis products in Brazil. Clever Leaves' Colombia facility being awarded Brazilian-GMP marks the company's fifth international official certification and further attests to the high-quality and premium standard practices that Clever Leaves upholds in its production. Clever Leaves is the first and only medicinal cannabis company globally who has GMP certifications from the EU, Colombia and Brazil. "The awarding of Brazilian-GMP certification signifies a major milestone for Clever Leaves by further highlighting our commitment to producing high-quality and safe cannabis products that are trusted internationally and meet the highest regulatory standards. The Brazilian market in particular has the potential to become the largest cannabis market in Latin America and one of the largest globally. We look forward to further developing our presence in Brazil through our partners, with whom we are already distributing finished cannabis products to medical patients in the country," said Andres Fajardo, CEO of Clever Leaves.

08:06 EDT Verizon to allow customers to customize plan in U.S. - Verizon customers can pay for only what they need. Everyone gets to customize their own plan, so each person, or family member, gets what they want - and everyone can save. Adjust, tweak and put your own spin on any plan you choose, anytime from the comfort of your phone with the My Verizon App. "We are always listening and reacting to our customers and now, more than ever, they want increased control and flexibility with their plans. They want plans to be simple and convenient, and of course, they want our best network and the best value," said Sowmyanarayan Sampath, CEO of Verizon Consumer Group. "myPlan gives customers the ability to pick and choose the perks they want, save on every one, and change anytime - that's real wireless freedom. Plus, savings from amazing partners that provide the best in content, entertainment and more."

08:05 EDT Sangamo appoints Lisa Rojkjaer Chief Medical Officer - Sangamo Therapeutics announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical development will be pivotal for us as we advance our wholly owned Fabry program toward a potential Phase 3 trial, progress our industry-leading CAR-Treg program TX200 through Phase 1/2, and further develop our pre-clinical pipeline of epigenetic regulation for the central nervous system. Her leadership will be invaluable as we seek to create targeted potential genomic medicines for patients suffering from serious genetic diseases for which there are few or no available treatments today."

08:04 EDT Adeia signs long-term IP license renewal with Cox Communications - Adeia announced that Cox Communications has entered into a long-term extension of its license to Adeia's media patent portfolio.

08:03 EDT BIO-key says 'positioned to deliver substantial top-line growth' in 2023 - "As anticipated, BIO-key achieved record quarterly revenue in Q1'23, reflecting our growing base of annual recurring revenue and customer momentum. Q1'23 results also reflected higher gross profit and lower operating expenses enabling BIO-key to trim its operating loss to ($0.3M) from ($1.0M) in Q1'22. Reflecting this progress and a growing pipeline of new and existing customer opportunities, including much larger projects, we are confident BIO-key is positioned to deliver substantial top-line growth and bottom-line improvements in FY 2023."

07:59 EDT Latch says Ring-creator Jamie Siminoff to take over as CEO later this year - Jason Keyes, Latch(LTCH) Interim CEO, said: "We are pleased to join forces with Jamie and his team as we continue on our current path of driving operational performance and sustainable growth. "A lifelong inventor and entrepreneur, Jamie Siminoff created Ring, a whole-home security company that was acquired by Amazon (AMZN) in 2018. .. "I'm excited to join the Latch team, which has built an incredible offering that users across the country enjoy and benefit from every day. Smart, secure access control is not only fundamental to real estate operators like myself, but also to residents and service providers. I look forward to combining Honest Day's Work with Latch to build a residential ecosystem that empowers building owners, operators, service providers, and residents alike."

07:53 EDT Vodafone down 5.5% to $10.60 after FY23 results

07:48 EDT LumiraDx says additional restructuring expected to reduce workforce by 40% - The company said, "The reductions in operating expenses reflect the majority of the benefit of the company's 2022 restructuring activities, but they do not yet reflect the additional restructuring announced by the company in April of this year. Additional restructuring activities are expected to reduce our global workforce by 40% with expense reductions of $36M per annum with the full impact from June 2023 onward."

07:40 EDT Cheniere Energy and KOSPO sign long-term LNG sale and purchase agreement - Cheniere Energy announced that Cheniere's subsidiary, Cheniere Marketing International has entered into a long-term liquefied natural gas sale and purchase agreemen with Korea Southern Power.Under the SPA, KOSPO has agreed to purchase approximately 0.4M tons per annum of LNG from Cheniere Marketing on a delivered ex-ship basis from 2027 through 2046, with a smaller annual quantity to be delivered starting in 2024. The purchase price for LNG to be delivered under the SPA prior to 2027 will be a market-based price, after which the purchase price will be indexed to the Henry Hub price, plus a fee. The volumes associated with the SPA from 2028 through 2046 are subject to a positive final investment decision with respect to the first train of the Sabine Pass Liquefaction Expansion Project . "We are pleased to enter into this long-term LNG contract with KOSPO, the leading power generation company in Korea, in support of KOSPO's growing natural-gas fired power generation capacity," said Jack Fusco, Cheniere's President and Chief Executive Officer. "This SPA is expected to support the SPL Expansion Project, and we are excited to build commercial momentum as the project's development progresses. This SPA further highlights Cheniere's leadership in providing flexible, cleaner burning energy supply to meet both the energy security needs and environmental goals of our customers in both the short and long term."

07:39 EDT G1 confirms risk of myelosuppressive events for patients receiving chemotherapy - G1 Therapeutics described recently presented real-world data that confirm a consistent risk of myelosuppressive events across patients with small cell lung cancer being treated with chemotherapy. These findings were presented in a poster session at the 2023 meeting of the International Society for Pharmacoeconomics and Outcomes Research, held May 7-10, 2023. "Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens," said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics. "Despite this, little data have been generated in this tumor type to help clarify and quantify the risk of myelosuppressive events across the spectrum of patients who are treated with chemotherapy for SCLC. For the first time, the results of these analyses show that all patients - of any age, gender, race, stage, ECOG or smoking status, or at any line of chemotherapy - are at similarly high risk for such myelosuppressive events. This continues to underscore the need to ensure that patients receive the most appropriate therapies to reduce that risk and to help improve their chemotherapeutic experience." Results showed that, among adult patients in this data set diagnosed with SCLC who received chemotherapy, grade greater than or equal to3 myelosuppression occurred in 60.9% of patients in the overall population. Further, more than half of the patients experienced grade greater than or equal to3 myelosuppression in all subgroups among the overall population, except one subgroup of patients for whom their SCLC stage was not documented at diagnosis.

07:38 EDT Futu Holdings' investment platform moomoo expands into Malaysia - Futu Holdings announced its expansion into Malaysia with its super investment platform, moomoo, introducing a suite of tech-driven offerings to promote financial inclusion. The company's wholly-owned Malaysian subsidiary has recently received the Approval-In-Principle for the Capital Markets Services License from the Securities Commission Malaysia.

07:38 EDT Pagaya sees FY23 adjusted EBITDA $15M-$30M - Pagaya backs previous FY23 views of Network Volume Expected to be between $7.5B and $8B;Total revenue and other income expected to be between $775M and $825M and adjusted EBITDA Expected to be between $15M and $30M.

07:36 EDT Blue Apron announces plans to shift to asset-light model through FreshRealm pact - Blue Apron announced plans for a long-term operations and logistics relationship with FreshRealm, a provider of fresh meals to top retailers nationwide, that would see the business shift to an asset-light model. The companies have signed a non-binding letter of intent for up to $50M payable to Blue Apron for the transfer of its operational infrastructure, as well as when transition, efficiency and product milestones are met. Blue Apron plans to continue to drive its core direct-to-consumer business, including the creation and marketing of its product, customer data, customer support and consumer technology. The company does not expect changes to its existing revenue streams as a result of this relationship. The company also plans to add new convenience product options for a broader consumer base in the future. Upon closing, and together with additional streamlining efforts Blue Apron plans to make, the transaction is expected to enhance the company's balance sheet and drive additional corporate product, technology, general and administrative efficiencies alongside the asset-light model to support the company's goal of profitability. The proposed transaction builds on Blue Apron's current relationship with FreshRealm, which is the manufacturer of the company's popular line of Heat & Eat meals. Once the transaction closes, Blue Apron expects to be able to accelerate product innovation with faster development and commercialization. Blue Apron also expects to be able to leverage FreshRealm's expertise, along with their full product capabilities of ready-to-heat and ready-to-cook meals, and other offerings. Over time, this relationship is also expected to open additional sales channels. At the closing of the transaction, Blue Apron would transfer its operational infrastructure to FreshRealm, including fulfillment centers, equipment, know-how and personnel. In consideration of the transaction, Blue Apron expects to issue to FreshRealm warrants in an amount equal to 19.9% of the company's then-outstanding common stock with an exercise price of $.01 per share on the closing date of the transaction. The parties intend to sign definitive agreements and close the transaction on or about June 9.

07:35 EDT Soligenix granted European patent for use of dusquetide in Oral Mucositis - Soligenix announced that the European Patent Office has granted a patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis". This granted patent builds on similar intellectual property issued in the United States, New Zealand, Japan, Australia and Singapore, as well as many pending patent applications in other jurisdictions worldwide. The granted claims will cover therapeutic uses of dusquetide and related innate defense regulator analogs, and adds to composition of matter claims for dusquetide and related analogs that have been issued in the U.S. and worldwide.

07:32 EDT MakeMyTrip says Go First insolvency could hurt air ticket supply - Along with its quarterly report, MakeMyTrip stated: "On May 2, 2023, Go Airlines (India) Limited, or Go First, being one of our top five domestic airline suppliers, filed an application for voluntary insolvency resolution proceedings before the National Company Law Tribunal, or NCLT, in India, citing the supply of faulty aircraft engines and failure of its engine supplier to replace them on time, which resulted in the grounding of half of its fleet and consequent operational and financial issues. On May 10, 2023, the NCLT admitted the application and granted protection to Go First by imposing a moratorium against recovery by lessors, lenders and other creditors of Go First. In addition, the NCLT has appointed an interim resolution professional to operate Go First and to maintain Go First as a going concern. As of the date hereof, Go First has suspended all flights until May 23, 2023. Such disruptions to the commercial aviation landscape may result in a reduction in the supply of air tickets available on our platform, which could negatively impact our gross bookings, air ticketing revenue and results from operating activities... In the meantime, MakeMyTrip has extended its cooperation to MakeMyTrip customers who have been impacted by the suspension of Go First flights."

07:32 EDT Wildpack Beverage appoints Izhar Basha to board of directors - Wildpack announces the appointment of Izhar Basha as a new member of its Board of Directors effective May 15, 2023. Izhar Basha is the founder, Chief Executive Officer, and majority shareholder of EHPlabs.

07:30 EDT Wildpack Beverage, Sandton continue to finalize convertible loan - Wildpack and Sandton continue to finalize the convertible loan described in the Company's press release dated April 19, 2023, without any material adjustments to the terms previously disclosed. Management expects to execute the Convertible Loan imminently, at which point it will likely be required to seek the shareholder consent of 50% plus 1 of the Company's issued securities and TSX Venture Exchange approval prior to closing. Sandton has already proven a strategic relationship for Wildpack by introducing the Company to a number of high-profile potential customers.

07:29 EDT Wildpack Beverage reports $6.2M in confirmed customer orders for April - Wildpack Beverage announces record total throughput of 35,641,630 cans, driven by new monthly records for brokering and filling throughput for the month of April 2023. The Company reported confirmed customer orders of $6,191,169, confirmed sales orders of 226, and new customer conversions of 41. During the month of April 2023, Wildpack achieved a total throughput of 35,641,630 cans; of which included decorated of 4,722,977, filled of 3,434,933, printed sleeves of 4,153,525, and brokered of 23,330,195 cans, notably setting new monthly records for brokering and filling throughput. In addition to the new monthly records for brokering and filling throughput, Wildpack also achieved a significant milestone in its total throughput, which was a year-over-year increase of 153%, setting a new record for the Company. Wildpack achieved overall plant utilization of 40% in April, the second consecutive month the Company achieved that milestone. Despite the ongoing relocation process of one of its co-packing facilities, which is factored into the overall plant utilization at zero, Wildpack Beverage has maintained elevated efficiency across its two east and west coast operating co-pack sites located in Las Vegas and Baltimore. The Company's success can be attributed to its strategic focus on customer satisfaction and commitment to efficiency, which have allowed it to maintain strong relationships with its existing customer base while consistently attracting new customers.

07:27 EDT On Holding reports Q1 DTC sales up 64% - Reports Q1: net sales through the direct-to-consumer ("DTC") sales channel increased 64.3% to CHF 137.0 million; net sales through the wholesale sales channel increased 86.0% to CHF 283.2 million; net sales in Europe, Middle East and Africa ("EMEA"), Americas and Asia-Pacific increased 51.6% to CHF 118.9 million, 91.9% to CHF 270.2 million and 89.4% to CHF 31.1 million, respectively; net sales from shoes, apparel and accessories increased 80.0% to CHF 400.5 million, 48.9% to CHF 16.9 million and 52.3% to CHF 2.8 million, respectively.

07:23 EDT Laser Photonics announces formation of semiconductor division - Laser Photonics announced the formation of its semiconductor division. Peter Evans, president of Laser Photonics, commented: "The recent passing of the CHIPS and Science Act of 2022 was a catalyst to leveraging our access to cutting-edge wafer dicing technology through ICT-Investments. This new, long-term growth opportunity expands on our disruptive CleanTech laser cleaning opportunity and provides a second potential high-growth opportunity for the Company. We plan to focus this new division on R&D and production of this technology and look forward to playing a part in strengthening supply chains and the semiconductor manufacturing industry as a whole."

07:22 EDT Constellation Software's Perseus completes acquisition of WinTech - Constellation Software announced that it has, through its Perseus Group, completed the purchase of Winklevoss Technologies. Founded in 1987 by Dr. Howard Winklevoss, WinTech is dedicated to being the software standard for defined benefit pension and other post-employment benefit plans. WinTech's customer base includes some of the world's top actuarial consultants, investment consulting firms, accounting firms, plan sponsors, plan administrators, and insurance companies.

07:20 EDT Fury Gold Mines appoints Brian Christie as board chair - Fury Gold Mines announced that independent Director Brian Christie will serve as Board Chair going forward and Jeffrey Mason will continue to serve as independent Director.

07:16 EDT Microbix Biosystems executes agreement to return Kinlytic urokinase to market - Microbix Biosystems announces execution of an agreement to return Kinlytic urokinase to market, initially for dissolving blood clots in venous catheters in the United States and to be followed by other geographies and clinical indications. Its Agreement is with Sequel Pharma, a specialty pharma company with expertise in developing and commercializing drugs for the U.S. market that is funded by a leading private equity firm. The Agreement provides for Sequel to fund and undertake the necessary work to return Kinlytic to the U.S. for the clinical indication of venous catheter clearance, currently a US$ 350 million per year market that is a monopoly. Microbix will receive a closing payment of $2M under the Agreement. Sequel and Microbix will now prepare for an updated consultation with the U.S. Food and Drug Administration to confirm that prior regulatory guidance received by Microbix remains pertinent. Should FDA guidance be satisfactory, the parties will undertake the work needed to file a supplementary Biologics Licensing Application filing, with funding for such work to be fully provided by Sequel. Upon a satisfactory FDA consultation, Sequel will make a further US$ 2.0 million payment to Microbix, followed by a US$ 1.0 million milestone on U.S. re-approval via sBLA, sales-driven milestone payments of up to US$ 30 million, and ongoing royalties targeted to be a double-digit percentage of net sales. Should the FDA consultation be unexpectedly negative, Sequel may terminate the Agreement and recoup US$ 1.0 million of the closing payment. Mike Anderson, CEO of Sequel commented, "We've completed extensive technical and market diligence on Kinlytic and are excited to partner with Microbix in bringing it back to market. It is important that safe, effective, and economic drugs such as Kinlytic are available to address the needs of millions of patients."

07:14 EDT Aravive announces Phase 3 trial design for batiraxcept - Aravive announced that the Company has received guidance from the U.S. Food and Drug Administration, FDA, on a registrational Phase 3 trial design for batiraxcept in clear cell renal cell carcinoma at an End-of-Phase 2 meeting. "We are very pleased to be advancing batiraxcept into Phase 3 development in ccRCC, having successfully completed our EOP2 meeting with the FDA," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "We believe our trial design and planned endpoint analyses are consistent with the FDA's guidance, and we look forward to initiating our registrational Phase 3 trial in the second half of 2023. Topline results are expected in 2025 and, if successful, will support a supplemental biologics license application submission in ccRCC."

07:13 EDT Lithium Ionic announces change of auditor - Lithium Ionic announces that the board of directors of the Company has appointed Deloitte as the Company's new auditor, replacing McGovern Hurley. There were no reservations in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor. There are no "reportable events" between the Company and the Former Auditor. In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Company's Audit Committee and will be filed on SEDAR accordingly.

07:11 EDT BioXcel Therapeutics announces data from Phase 1b trial of BXCL501 - BioXcel Therapeutics announced positive top-line data from its Phase 1b multiple ascending dose trial of BXCL501 sublingual film. BXCL501 is the Company's proprietary, orally dissolving film under investigation for the treatment of agitation associated with neuropsychiatric disorders and as a potential adjunctive treatment in Major Depressive Disorder. The trial was designed to evaluate the safety and tolerability of repeat dosing of BXCL501 in healthy volunteers as a single agent and in combination with antidepressant duloxetine. These results support dose selection for a Phase 2 proof-of-concept trial to evaluate BXCL501 in combination with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitor to potentially accelerate antidepressant activity in patients with MDD. "This positive outcome supports the potential market expansion opportunity for our lead asset, BXCL501, into chronic neuropsychiatric disorders," said Vimal Mehta, CEO of BioXcel Therapeutics. "Our focus has been on developing innovative treatments for the millions of patients who are impacted by agitation episodes, including Alzheimer's disease. Our first drug, IGALMI(TM), is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. We believe these new data present a transformative opportunity beyond acute treatment for the BXCL501 program, including treatment for MDD. This drug candidate has a pipeline-within-a-product potential across a broad range of neuropsychiatric conditions." The study was a double-blind, placebo-controlled evaluation of BXCL501 for once- and twice-daily administration over seven days in ascending dose groups. The study's primary objectives were to assess the safety, tolerability, and pharmacokinetics of BXCL501 in healthy volunteers in multiple ascending doses. The trial successfully met the primary endpoints.

07:10 EDT Arko Corp. increases share repurchase program from $50M to $100M - ARKO announced that its Board of Directors increased the Company's previously authorized share repurchase program by an additional $50 million. The Company now has availability to repurchase up to an aggregate amount of approximately $59 million of the Company's outstanding shares of common stock under this newly expanded repurchase plan. "We believe that repurchasing our shares is a compelling use of our capital resources," said Arie Kotler, Chairman, President, and Chief Executive Officer of ARKO. "We are encouraged by the traction of our initiatives and progress of our merchandise and fuel strategy to maximize gross profit dollars, and we remain confident in the continued growth of our business. Our last quarter results were strong, as we continued to deliver robust in-store performance as a result of our focus on our key initiatives. We remain deeply committed to maximizing stockholder value creation, and this increase of our repurchase program is aligned with ARKO's capital allocation framework ensuring that in addition to growth through M&A and organic initiatives, we also return capital to our stockholders through our share repurchase program."

07:09 EDT Genenta Science to provide update on lead product temferon - Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science will be presenting the company cell-based platform harnessing the power of hematopoietic stem cells to provide durable, safe, and well tolerated treatment for solid tumors at several upcoming scientific congresses. Prof. Luigi Naldini will provide updates on the efficacy of Genenta's lead product candidate, Temferon, in pre-clinical solid tumor models and preliminary clinical biological data confirming in patients at these congresses. Genenta has a deep pipeline of potential candidates and therapeutic combinations at different stages of development. The drug at the most advanced stage of development is called Temferon, and is currently in clinical trials of humans - Phase 1/2a. Temferon uses the patient's own stem cells modified with Genenta's platform to express interferon alpha in the tumor - a well-known immunomodulatory protein that has been used in the clinic for decades for the treatment of a variety of cancers, but with limited current use because of the systemic tolerability. Genenta's platform makes it possible to precisely avoid exposing the whole body to not tolerable concentrations and to selectively bring therapeutic activity into the tumor. From pre-clinical experiments, it has been observed that Temferon allows the immune system to see the tumor and mount an effective immune response. Food and Drug Administration has granted Orphan Drug Designation to Temferon for the treatment of glioblastoma multiforme/

07:09 EDT AlloVir appoints Cintia Piccina Chief Commercial Officer - AlloVir announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 1. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology product launches and product growth. She will be instrumental in building and driving AlloVir's capabilities, particularly in support of our lead investigational product, posoleucel, a multi-virus specific T cell therapy targeting six devasting viral infections," said Diana Brainard, MD, Chief Executive Officer, AlloVir. "Her proven leadership in building commercial strategies, talent, and teams, will be critical to AlloVir as we advance toward data readouts anticipated next year for our three registrational trials currently underway."

07:08 EDT Kamada receives receipt of market authorization for Glassia - Kamada announced that Swissmedic has granted marketing authorization for Glassia in Switzerland for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary Alpha-1 antitrypsin deficiency, AATD. "Switzerland is the first European country to approve Glassia for AATD, representing a significant milestone for Kamada, in a market which is currently estimated to be over $15 million annually," said Amir London, Kamada's Chief Executive Officer. "The commercial launch of the product in Switzerland is expected to occur during the second half of this year, upon obtaining the required reimbursement coverage. To ensure wide access to eligible patients, we are excited to partner with the IDEOGEN Group, a company focused on the commercialization of specialty medicines for rare diseases across Europe."

07:07 EDT YS Biopharma's PIKA Rabies Vaccine approved for Phase 3 trial in Pakistan - YS Biopharma announced its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from the Drug Regulatory Authority of Pakistan. The Phase 3 clinical trial will evaluate the safety and immunogenicity of the company's PIKA Rabies Vaccine in preventing rabies infection. The Phase 3 study is a multi-center, multi-country study set to be conducted in Singapore, the Philippines, and Pakistan in 2023. YS Biopharma anticipates conducting Phase 3 clinical trials in healthy volunteers without exposure to animal bites, with an estimated 4,500 subjects in total. The company is also planning to conduct more advanced clinical trials in China. Pending the successful completion of Phase 3 trials, the company intends to submit the New Drug Application or Biologics License Application for the PIKA Rabies Vaccine to regulatory authorities in China and countries in Asia and other continents.

07:06 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 7,200 shares of EyePoint Pharmaceuticals common stock to three new employees. The stock options were granted on May 15, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $6.00 per share, the closing price of EyePoint Pharmaceuticals' common stock on May 15, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:05 EDT Labcorp, Providence expand longstanding strategic relationship - Labcorp announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations. Through the agreement, Labcorp will acquire Providence Oregon's outreach laboratory business and select assets in Oregon. Providence Oregon will maintain operation and ownership of certain anatomic pathology and genomics outreach testing and its hospital laboratories in the region. The transaction is expected to close later in 2023 and is subject to customary closing conditions and applicable regulatory approvals.

07:04 EDT Becton Dickinson announces FDA clearance for BD Kiestra MRSA imaging application - Becton Dickinson announced 510(k) clearance from the FDA for the new BD Kiestra Methicillin-resistant Staphylococcus aureus, or MRSA, imaging application that uses artificial intelligence, or AI, to interpret bacterial growth and release negative specimens with minimal human interaction.

07:04 EDT ProQR Therapeutics sees cash runway into mid-2026 - At March 31, 2023, ProQR held cash and cash equivalents of EUR 139.0 million, compared to EUR 94.8 million at December 31, 2022. Net cash generated by operating activities during the three-month period ended March 31, 2023 was EUR 44.7 million, compared to EUR 20.5 million used for the same period last year.

06:54 EDT Nuscale Power and Nucor sign MOU for nuclear reactors to power steel mills - NuScale Power (SMR) and Nucor (NUE) have signed a Memorandum of Understanding - MOU - to explore co-locating NuScale's VOYGR small modular nuclear reactor power plants to provide clean, reliable baseload electricity to Nucor's scrap-based Electric Arc Furnace steel mills. The companies will also explore an expanded manufacturing partnership through which Nucor would supply Econiq, its net-zero steel products, for NuScale projects. As part of the MOU, the companies will evaluate site suitability, transmission interconnection capabilities and capital costs for potential NuScale plants to be sited near and provide carbon free electricity to Nucor EAF steel mills. In addition, NuScale will study the feasibility of siting a manufacturing facility for NuScale Power Modules near a Nucor facility. The agreement strengthens NuScale's partnership with Nucor, which invested $15M in NuScale in 2022.

06:27 EDT Futu Holdings falls 12% to $37.86 after removing Futubull app from China stores

06:05 EDT Eneti's Seajacks subsidiary signs reservation agreemeent in Asia Pacific region - MEneti's Seajacks UK wholly-owned subsidiary has signed a reservation agreement for its NG 5500 vessel, Seajacks Zaratan, for employment in the Asia Pacific region for between five and six months. The reservation agreement, will, if converted into a contract, generate between approximately EUR32.5M and EUR38.0M of revenue after estimated project costs and would commence in 2Q24.

06:03 EDT Futu Holdings to remove Futubull app from mainland China app stores - Futu Holdings has decided to remove the Futubull app from app stores in Mainland China from May 19, 2023. In response to the Chinese Securities and Regulatory Commission's rectification requirements on cross-border securities business, Futu will remove the Futubull app from app stores in Mainland China in order to bring its operations into full compliance with such regulatory principle. After the Futubull app is removed from app stores in Mainland China, existing Mainland China clients can still make trades on Futubull, and the relevant services and business will not be affected in any way by the removal. Users outside Mainland China may also continue to download and use Futubull without any interruption.

05:54 EDT Vodafone to cut 11,000 jobs over three years - Vodafone said: "Our target is to be a best-in-class telco in Europe and Africa, and become Europe's leading platform for Business... To execute the change in these four areas, we have an action plan already underway, focused around three priorities: Customers, Simplicity and Growth. Early examples of this action plan include: Customers: Significant investment reallocated in FY24 towards customer experience and brand; Simplicity: 11,000 role reductions planned over three years, with both HQ and local markets simplification; Growth: Germany turnaround plan, continued pricing action and strategic review in Spain."

05:25 EDT Stellantis signs binding agreement to acquire 33.3% stake in Symbio - Faurecia, a company of the Forvia group, Michelin and Stellantis announce the signing of a binding agreement for Stellantis to acquire 33.3% stake in Symbio. Faurecia and Michelin will remain shareholders with 33.3% holding each. The announcement is a significant step in the decarbonization of the mobility industry and illustrates Symbio's technological excellence in hydrogen fuel cell innovations. The addition of Stellantis as a shareholder will boost Symbio's development across Europe and in the U.S. Symbio plans to produce 50,000 fuel cells per year by 2025, leveraging its Saint-Fons state-of-the-art gigafactory, which will start production in the second half of 2023. In 2022, Symbio announced the implementation of its HyMotive project aimed at accelerating its industrialization and the development of disruptive innovations, a project that will enable the company to reach a total annual production capacity in France of 100,000 systems by 2028 with the creation of 1,000 jobs in France. The transaction is subject to customary regulatory approvals. Closing is expected in the third quarter of 2023.